

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 12	369	N/A	158v6	Pregnant women that had HBsAg testing	This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy	Process	No
PRIME 35	66	0002	146v6	Appropriate Testing for Children with Pharyngitis	Percentage of children 3-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode	Process	Yes
PRIME 36	236	0018	165v6	Controlling High Blood Pressure	Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period	Outcome	Yes
PRIME 37-A	238	0022	156v6	Use of High-Risk Medications in the Elderly	Percentage of patients 66 years of age and older who were ordered high-risk medications. *Two rates are reported. A) Percentage of patients who were ordered at least one high-risk medication.	Process	Yes
PRIME 37-B	238	0022	156v6	Use of High-Risk Medications in the Elderly	Percentage of patients 66 years of age and older who were ordered high-risk medications. *Two rates are reported. B) Percentage of patients who were ordered at least two different high- risk medications.	Process	Yes
PRIME 38-BHW	239	0024	155v6	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. *Three rates are reported. *Percentage of patients with height, weight, and body mass index (BMI) percentile documentation.	Process	No
PRIME 38-BHW-1	239	0024	155v6	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Percentage of patients with height, weight, and body mass index (BMI) percentile documentation. *Report a total score, and each of the following strata: - Stratum 1 - Patients age 3-11	Process	No
PRIME 38-BHW-2	239	0024	155v6	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Percentage of patients with height, weight, and body mass index (BMI) percentile documentation. *Report a total score, and each of the following strata: - Stratum 2 - Patients age 12-17	Process	No

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 38-CN	239	0024	155v6	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. *Three rates are reported. Percentage of patients with counseling for nutrition.	Process	No
PRIME 38-CN-1	239	0024	155v6	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Percentage of patients with counseling for nutrition. *Report a total score, and each of the following strata: - Stratum 1 - Patients age 3-11	Process	No
PRIME 38-CN-2	239	0024	155v6	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Percentage of patients with counseling for nutrition. *Report a total score, and each of the following strata: - Stratum 2 - Patients age 12-17	Process	No
PRIME 38-PA	239	0024	155v6	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. *Three rates are reported. Percentage of patients with counseling for physical activity.	Process	No
PRIME 38-PA-1	239	0024	155v6	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Percentage of patients with counseling for physical activity. *Report a total score, and each of the following strata: - Stratum 1 - Patients age 3-11	Process	No
PRIME 38-PA-2	239	0024	155v6	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Percentage of patients with counseling for physical activity. *Report a total score, and each of the following strata: Stratum 2 - Patients age 12-17	Process	No
PRIME 39	226	0028	138v6	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user	Process	No
PRIME 40	112	2372	125v6	Breast Cancer Screening	Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer	Process	No

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 41	309	0032	124v6	Cervical Cancer Screening	Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria: * Women age 21-64 who had cervical cytology performed every 3 years * Women age 30-64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years	Process	No
PRIME 42	310	0033	153v6	Chlamydia Screening for Women	Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period	Process	No
PRIME 42-1	310	0033	153v6	Chlamydia Screening for Women	Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period. *Report a total score, and each of the following strata: - Stratum 1: Patients age 16-20	Process	No
PRIME 42-2	310	0033	153v6	Chlamydia Screening for Women	Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period. *Report a total score, and each of the following strata: - Stratum 2: Patients age 21-24	Process	No
PRIME 43	113	0034	130v6	Colorectal Cancer Screening	Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer.	Process	No
PRIME 44	N/A	0036	126v5	Use of Appropriate Medications for Asthma	Percentage of patients 5-64 years of age who were identified as having persistent asthma and were appropriately ordered medication during the measurement period.	Process	No
PRIME 44-1	N/A	0036	126v5	Use of Appropriate Medications for Asthma	Percentage of patients 5-64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period. *Report a total score, and each of the following strata: - Stratum 1: Patients age 5-11	Process	No
PRIME 44-2	N/A	0036	126v5	Use of Appropriate Medications for Asthma	Percentage of patients 5-64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period. *Report a total score, and each of the following strata: - Stratum 2: Patients age 12-18	Process	No
PRIME 44-3	N/A	0036	126v5	Use of Appropriate Medications for Asthma	Percentage of patients 5-64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period. *Report a total score, and each of the following strata: - Stratum 3: Patients age 19-50	Process	No
PRIME 44-4	N/A	0036	126v5	Use of Appropriate Medications for Asthma	Percentage of patients 5-64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period. *Report a total score, and each of the following strata: - Stratum 4: Patients age 51-64	Process	No

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 45	240	0038	117v6	Childhood Immunization Status	Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday	Process	No
PRIME 46	110	0041	147v7	Preventive Care and Screening: Influenza Immunization	Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization	Process	No
PRIME 47	111	0043	127v6	Pneumococcal Vaccination Status for Older Adults	Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine	Process	No
PRIME 48	N/A	0052	166v7	Use of Imaging Studies for Low Back Pain	Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.	Process	Yes
PRIME 49	117	0055	131v6	Diabetes: Eye Exam	Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior to the measurement period	Process	No
PRIME 50	163	0056	123v6	Diabetes: Foot Exam	The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a foot exam (visual inspection and sensory exam with mono filament and a pulse exam) during the measurement year	Process	No
PRIME 51	1	0059	122v6	Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)	Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.	Outcome	Yes
PRIME 53	119	0062	134v6	Diabetes: Medical Attention for Nephropathy	The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.	Process	No
PRIME 54	N/A	N/A	163v5	Diabetes: Low Density Lipoprotein (LDL-C) Control (< 100 mg/dL)	Percentage of patients 18-75 years of age with diabetes whose LDL-C was adequately controlled (<100 mg/dL) during the measurement period.	Outcome	No
PRIME 55	204	0068	164v6	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet	Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antiplatelet during the measurement period.	Process	No
PRIME 56	65	0069	154v6	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode	Process	Yes

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 57-A	7	0070	145v6	Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)	Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have prior MI OR a current or prior LVEF < 40% who were prescribed beta- blocker therapy. A) Percentage of patients aged 18 years and older with a diagnosis of CAD or history of cardiac surgery seen within a 12 month period and who have a current or prior LVEF < 40% who were prescribed beta-blocker therapy	Process	No
PRIME 57-B	7	0070	145v6	Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)	Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have prior MI OR a current or prior LVEF < 40% who were prescribed beta- blocker therapy. B) Percentage of patients aged 18 years and older with a diagnosis of CAD or history of cardiac surgery seen within a 12 month period who have a prior (within the past 3 years) myocardial infarction who were prescribed beta-blocker therapy	Process	No
PRIME 58-A	N/A	N/A	182v6	Ischemic Vascular Disease (IVD): Complete Lipid Profile and LDL-C Control (<100 mg/dL)	Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose most recent Low-density Lipoprotein (LDL-C) was adequately controlled (< 100 mg/dL) A) Patients 18 years of age and older with a visit during the measurement year who had an AMI, CABG, or PCI during the 12 months prior to the measurement year or who had a diagnosis of IVD during the measurement year and with a complete lipid profile performed during the measurement period.	Process	No
PRIME 58-B	N/A	N/A	182v6	Ischemic Vascular Disease (IVD): Complete Lipid Profile and LDL-C Control (<100 mg/dL)	Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose most recent Low-density Lipoprotein (LDL-C) was adequately controlled (< 100 mg/dL) B) Patients 18 years of age and older with a visit during the measurement year who had an AMI, CABG, or PCI during the 12 months prior to the measurement year or who had a diagnosis of IVD during the measurement year and whose most recent LDL-C level performed during the measurement period is <100 mg/dL	Process	No
PRIME 59	5	0081/2907	135v6	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge	Process	No

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 60	8	0083/2908	144v6	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge	Process	No
PRIME 61	318	0101	139v6	Falls: Screening for Future Fall Risk	Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period	Process	Yes
PRIME 64-A	366	0108	136v7	ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication	Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. *Two rates are reported. A) Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.	Process	No
PRIME 64-B	366	0108	136v7	ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication	Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. *Two rates are reported. B) Percentage of children 6-12 years of age who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.	Process	No
PRIME 65	134	0418	2v7	Preventive Care and Screening: Screening for Depression and Follow-Up Plan	Percentage of patients aged 12 years and older screened for depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen	Process	No
PRIME 66	130	0419	68v7	Documentation of Current Medications in the Medical Record	Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosage, frequency and route of administration.	Process	Yes
PRIME 67	128	0421	69v6	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter Normal Parameters : Age 18 years and older BMI => 18.5 and < 25 kg/m2	Process	No
PRIME 69-A	371	0712	160v6	Depression Utilization of the PHQ-9 Tool	Patients age 18 and older with the diagnosis of major depression or dysthymia who have a Patient Health Questionnaire (PHQ-9) tool administered at least once during a 4-month period ' January 2018- April 2018 ' in which there was a qualifying visit.	Process	No

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 69-B	371	0712	160v6	Depression Utilization of the PHQ-9 Tool	Patients age 18 and older with the diagnosis of major depression or dysthymia who have a Patient Health Questionnaire (PHQ-9) tool administered at least once during a 4-month period 'May 2018- August 2018' in which there was a qualifying visit.	Process	No
PRIME 69-C	371	0712	160v6	Depression Utilization of the PHQ-9 Tool	Patients age 18 and older with the diagnosis of major depression or dysthymia who have a Patient Health Questionnaire (PHQ-9) tool administered at least once during a 4-month period 'September 2018- December 2018' in which there was a qualifying visit.	Process	No
PRIME 72-H	N/A	N/A	61v6	Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed	Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL-C test has been performed. There are three criteria for this measure based on the patient's risk category. When a patient could be included in multiple risk categories, the "higher" level of risk will be utilized. (High Risk) - All patients aged 20 through 79 years who have CHD or CHD Risk Equivalent OR 10-Year Framingham Risk > 20% and who had a fasting LDL-C test performed or a calculated LDL-C during the measurement period	Process	No
PRIME 72-M	N/A	N/A	61v6	Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed	Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL-C test has been performed. There are three criteria for this measure based on the patient's risk category. When a patient could be included in multiple risk categories, the "higher" level of risk will be utilized. (Moderate Risk) - All patients aged 20 through 79 years who have 2 or more Major CHD Risk Factors OR 10-Year Framingham Risk 10-20% and who had a fasting LDL-C test performed or a calculated LDL-C during the measurement period	Process	No
PRIME 72-L	N/A	N/A	61v6	Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed	Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL-C test has been performed. There are three criteria for this measure based on the patient's risk category. When a patient could be included in multiple risk categories, the "higher" level of risk will be utilized. (Low Risk) - All patients aged 20 through 79 years who have 0 or 1 Major CHD Risk Factors OR 10-Year Framingham Risk <10% and who had a fasting LDL-C test performed or a calculated LDL-C during the measurement period or up to four (4) years prior to the current measurement period	Process	No
PRIME 73	281	2872	149v6	Dementia: Cognitive Assessment	Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12 month period	Process	No
PRIME 75	317	N/A	22v6	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated	Process	No

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 76	372	1401	82v5	Maternal Depression Screening	The percentage of children who turned 6 months of age during the measurement year, who had a face-to-face visit between the clinician and the child during child's first 6 months, and who had a maternal depression screening for the mother at least once between 0 and 6 months of life.	Process	No
PRIME 80	N/A	0061	N/A	Comprehensive Diabetes Care: Blood Pressure Control (<140/90 mm Hg)	The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) whose most recent blood pressure level taken during the measurement year is <140/90 mm Hg.	Outcome	No
PRIME 82	N/A	N/A	179v5	ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range	Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the measurement period.	Outcome	No
PRIME 85	373	N/A	65v7	Hypertension: Improvement in Blood Pressure	Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.	Outcome	Yes
PRIME 86	23	0239	N/A	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	Percentage of surgical patients aged 18 years and older undergoing procedures for which venous thromboembolism (VTE) prophylaxis is indicated in all patients, who had an order for Low Molecular Weight Heparin(LMWH), Low- Dose Unfractionated Heparin(LDUH), adjusted-dose warfarin, fondaparinux or mechanical prophylaxis to be given within 24 hours prior to incision time or within 24 hours after surgery end time.	Process	Yes
PRIME 87-A	438	N/A	347v1	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	Percentage of the following patients-all considered at high risk of cardiovascular events-who were prescribed or were on statin therapy during the measurement period A) Adults aged >= 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD)	Process	No
PRIME 87-B	438	N/A	347v1	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	Percentage of the following patients-all considered at high risk of cardiovascular events-who were prescribed or were on statin therapy during the measurement period B) Adults aged >=21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia	Process	No
PRIME 87-C	438	N/A	347v1	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	Percentage of the following patients-all considered at high risk of cardiovascular events-who were prescribed or were on statin therapy during the measurement period C) Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL	Process	No
PRIME 88-1	305	0004	137v6	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. *Two rates are reported. 1) Percentage of patients who initiated treatment within 14 days of the diagnosis.	Process	No

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 88-1-S1	305	0004	137v6	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. 1) Percentage of patients who initiated treatment within 14 days of the diagnosis. *Report a total score, and each of the following strata: Stratum 1: Patients age 13-17	Process	No
PRIME 88-1-S2	305	0004	137v6	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. 1) Percentage of patients who initiated treatment within 14 days of the diagnosis. *Report a total score, and each of the following strata: Stratum 2: Patients age >=18	Process	No
PRIME 88-2	305	0004	137v6	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. *Two rates are reported. 2) Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.	Process	No
PRIME 88-2-S1	305	0004	137v6	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. 2) Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit. *Report a total score, and each of the following strata: Stratum 1: Patients age 13-17	Process	No
PRIME 88-2-S2	305	0004	137v6	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. 2) Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit. *Report a total score, and each of the following strata: Stratum 2: Patients age >=18	Process	No
PRIME 89	370	0710	159v6	Depression Remission at Twelve Months	Patients age 18 and older with major depression or dysthymia and an initial Patient Health Questionnaire (PHQ- 9) score greater than nine who demonstrate remission at twelve months (+/- 30 days after an index visit) defined as a PHQ-9 score less than five. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment.	Outcome	Yes
PRIME 90	374	N/A	50v6	Closing the Referral Loop: Receipt of Specialist Report	Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred	Process	Yes
PRIME 91	402	N/A	N/A	Tobacco Use and Help with Quitting Among Adolescents	The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user.	Process	No

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 92	431	2152	N/A	Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling	Percentage of patients aged 18 years and older who were screened at least once within the last 24 months for unhealthy alcohol use using a systematic screening method AND who received brief counseling if identified as an unhealthy alcohol user	Process	No
PRIME 93-H	N/A	N/A	64v6	Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDL-C)	Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose risk-stratified fasting LDL-C is at or below the recommended LDL-C goal. (High Risk) - All patients aged 20 through 79 years who had a fasting LDL-C or a calculated LDL-C test performed during the measurement period and have CHD or CHD Risk Equivalent OR 10 year Framingham risk > 20% and whose most recent fasting LDL-C test result is in good control, defined as <100 mg/dL	Process	No
PRIME 93-M	N/A	N/A	64v6	Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDL-C)	Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL-C test has been performed. There are three criteria for this measure based on the patient's risk category. When a patient could be included in multiple risk categories, the "higher" level of risk will be utilized. (Moderate Risk) - All patients aged 20 through 79 years who had a fasting LDL-C or a calculated LDL-C test performed during the measurement period and have 2 or more Major CHD Risk Factors OR 10 year Framingham Risk 10-20% and whose most recent fasting LDL-C test result is in good control, defined as <130 mg/dL	Process	No
PRIME 93-L	N/A	N/A	64v6	Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDL-C)	Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL-C test has been performed. There are three criteria for this measure based on the patient's risk category. When a patient could be included in multiple risk categories, the "higher" level of risk will be utilized. (Low Risk) - All patients aged 20 through 79 years who had a fasting LDL-C or a calculated LDL-C test performed up to 4 years prior to the current measurement period and have 0 or 1 Major CHD Risk Factors OR 10 year Framingham risk <10% and whose most recent fasting LDL-C test result is in good control, defined as <160 mg/dL	Process	No
PRIME 94	N/A	1392	N/A	Well Child Visits in the first 15 months of life	The percentage of children 15 months old who had the recommended number of well-child visits with a PCP during their first 15 months of life.	Process	No
PRIME 95	N/A	1516	N/A	Well Child Visits in 3rd, 4th, 5th, and 6th yrs of life	The percentage of children 3-6 years of age who had one or more well-child visits with a PCP during the measurement year.	Process	No
PRIME 96	N/A	N/A	N/A	Adolescent Well Care Visits	The percentage of children 12–21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year	Process	No
PRIME 97	394	1407	N/A	Immunizations for Adolescents	The percentage of adolescents 13 years of age who had the recommended immunizations by their 13th birthday	Process	No

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 99-1	N/A	0047	N/A	Pharmacologic Therapy for Persistent Asthma	Percentage of patients aged 5 years and older with a diagnosis of persistent asthma who were prescribed long-term control medication *Three rates are reported for this measure: 1. Patients prescribed inhaled corticosteroids (ICS) as their long term control medication	Process	No
PRIME 99-2	N/A	0047	N/A	Pharmacologic Therapy for Persistent Asthma	Percentage of patients aged 5 years and older with a diagnosis of persistent asthma who were prescribed long-term control medication *Three rates are reported for this measure: 2. Patients prescribed other alternative long term control medications (non-ICS)	Process	No
PRIME 99-3	N/A	0047	N/A	Pharmacologic Therapy for Persistent Asthma	Percentage of patients aged 5 years and older with a diagnosis of persistent asthma who were prescribed long-term control medication *Three rates are reported for this measure: 3. Total patients prescribed long-term control medication	Process	No
PRIME 100	ABFM8	N/A	N/A	Measuring the Value-Functions of Primary Care: Provider Level Continuity Measure	Bice-Boxerman Continuity of Care Primary Care Physician Measure (BB-COC-PC). At a patient-level, BB-COC is a measure that considers the dispersion of primary care visits across providers, such that patients with higher scores have most of their primary care visits to the same provider or a small number of providers while those lower scores see a larger number providers. Formally, an individual BB-COC score is calculated as follows: $BB-COC = \frac{\sum_{i=1}^k n_i^2 - N}{N(N-1)} \quad (1)$ where k is the number of providers, n _i is the number of visits to provider i, and N is the total number of visits. (Note that it is necessary that the patient has at least two visits.) We will calculate the physician-level continuity measure for all patients as follows: $BB-COC-PC = \frac{\sum_1^k [(BB-COC)(n_k)]}{N*(n_k)} \quad (2)$ Where BB-COC is the individual patient continuity score, n is number of total primary care visits for patient k during the study period, and N is the total number of patients seen by the physicians during the study period. This approach gives greater weight to patients with more visits.	Structure	Yes
PRIME 101	ABFM7	N/A	N/A	Pain Brought Under Control within the first three visits	Percent of patients 18 and older who report being uncomfortable because of pain at the initial palliative care assessment who report pain was brought to a comfortable level (e.g. "Comfortable? Yes/No", "mild" or pain score < 4) within the first three visits	Outcome	Yes
PRIME 102	ABFM5	N/A	N/A	Palliative Care—Treatment Preferences	The percentage of adult patients 18 and older with documentation of preferences for life-sustaining treatments within the first three visits	Process	Yes
PRIME 103	ABFM4	N/A	N/A	Palliative Care – Spiritual Assessment	Percentage of adult patients 18 and older and/or their caregiver receiving a palliative care visit with documentation of a discussion of spiritual/religious concerns or documentation that the they did not want to discuss during the first three visits	Process	Yes

ABFM PRIME Registry 2018 Measures

Registry ID	QPP#	NQF#	CMS#	Measure Title	Description	Measure Type	High Priority
PRIME 104	ABFM6	N/A	N/A	Palliative Care Timely Dyspnea Screening & Treatment	Percentage of palliative care adult patients 18 years and older who were screened for dyspnea during the initial palliative care encounter or documentation that a screening was attempted AND for those with moderate/severe dyspnea or who are uncomfortable due to dyspnea who receive treatment within 1 day of screening.	Process	Yes
PRIME 105	ABFM3	N/A	N/A	Patients Treated with an Opioid Who Are Given a Bowel Regimen	Percentage of adults 18 and older treated with an opioid that are offered/prescribed a bowel regimen during the same visit or documentation of reason for why this was not needed	Process	Yes
PRIME 106	ABFM1	N/A	N/A	All Patients Who Die an Expected Death with an ICD that Has Been Deactivated	Percentage of adult 18 and older patients in any care setting who die an expected death from cancer or other terminal illness and who have an implantable cardioverter-defibrillator (ICD) in place at the time of death that was deactivated prior to death or there is documentation why it was not deactivated	Process	Yes
PRIME 107	ABFM2	N/A	N/A	Patients Admitted to ICU who Have Care Preferences Documented	Percentage of adult 18 and older patients admitted to ICU who receive palliative care and survive at least 2 days who have their care preferences documented within 2 days OR documentation as to why this was not done.	Process	Yes
PRIME 108	N/A	1628	N/A	Patients with Advanced Cancer Screened for Pain at Outpatient Visits	Adult patients with advanced cancer who are screened for pain with a standardized quantitative tool at each outpatient visit	Process	No
PRIME 109	N/A	N/A	N/A	Palliative Care Initial Encounter Pain Screening	The percentage of palliative care adult patients 18 and older who were screened for pain during the initial palliative care encounter or documentation that a screening was attempted	Process	No
PRIME 110	377	N/A	90v7	Functional Status Assessments for Congestive Heart Failure	Percentage of patients 65 years of age and older with congestive heart failure who completed initial and follow-up patient-reported functional status assessments	Process	Yes
PRIME 111	379	N/A	74v7	Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists	Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.	Process	No
PRIME 112	109	N/A	N/A	Osteoarthritis (OA): Function and Pain Assessment	Percentage of patient visits for patients aged 21 years and older with a diagnosis of osteoarthritis (OA) with assessment for function and pain	Process	Yes
PRIME 113	24	0045	N/A	Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older	Percentage of patients aged 50 years and older treated for a fracture with documentation of communication, between the physician treating the fracture and the physician or other clinician managing the patient's on-going care, that a fracture occurred and that the patient was or should be considered for osteoporosis treatment or testing. This measure is reported by the physician who treats the fracture and who therefore is held accountable for the communication	Process	Yes
PRIME 114	418	0053	N/A	Osteoporosis Management in Women who have had a fracture	The percentage of women age 50-85 who suffered a fracture and who either had a bone mineral density test or received a prescription for a drug to treat osteoporosis in the six months after the fracture	Process	No
PRIME 115	39	0046	N/A	Screening for Osteoporosis for Women Aged 65-85 Years of Age	Percentage of female patients aged 65-85 years of age who ever had a central dual-energy X-ray absorptiometry (DXA) to check for osteoporosis	Process	No
PRIME 116	131	0420	N/A	Pain assessment and follow-up	Percentage of visits for patients aged 18 years and older with documentation of a pain assessment using a standardized tool(s) on each visit AND documentation of a follow-up plan when pain is present	Process	Yes